Liquiritigenin Ameliorates Metabolic Dysfunction‐Associated Steatotic Liver Disease via AMPK ‐Mediated Dual Activation of PPARα / PPARγ
Food Science & Nutrition · 2026-11 · 14 (11)
DOI: 10.1002/fsn3.72578 ↗Kurz gefasst
Fachartikel in der Zeitschrift Food Science & Nutrition, online erschienen am 08.11.2026. Verfasst von Yu Jung Heo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Science Ajou University School of Medicine Suwon Republic of Korea. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is characterized by hepatic triglyceride accumulation and chronic inflammation resulting from impaired fatty acid (FA) oxidation and dysregulated metabolic signaling. Liquiritigenin (LQ) exhibits diverse pharmacological activities; however, its role in MASLD and the underlying mechanisms remain unclear. This study aimed to evaluate the therapeutic effects of LQ against MASLD and elucidate its molecular mechanisms, focusing on PPARα/PPARγ activation and AMPK signaling. The effects of LQ were examined in a high‐fat diet (HFD)‐induced MASLD mouse model and in free fatty acid (FFA)‐treated HepG2 cells. Male C57BL/6J mice were fed an HFD for 14 weeks, and LQ was administered during the final 2 weeks. Metabolic parameters, hepatic lipid accumulation, and signaling pathways were analyzed using biochemical and molecular assays and glucose and insulin tolerance tests. LQ markedly reduced hepatic triglyceride content and serum AST and ALT levels in HFD‐fed mice and improved glucose intolerance and insulin resistance. LQ increased AMPK phosphorylation and the expression of SIRT1, PGC‐1α, PPARα, and PPARγ while suppressing SREBF1 expression and upregulating FA oxidation‐related genes. In FFA‐treated HepG2 cells, LQ activated AMPK, improved insulin signaling (p‐AKT and p‐IRS1), enhanced FA oxidation‐related gene expression, and reduced pro‐inflammatory cytokine levels. Pharmacological inhibition of AMPK abolished LQ‐induced metabolic improvements. In conclusion, LQ attenuates MASLD progression by restoring hepatic metabolic homeostasis through AMPK activation and dual induction of PPARα and PPARγ, promoting FA oxidation and improving insulin sensitivity. Hence, LQ could be a potential natural therapeutic candidate for MASLD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Medical Science Ajou University School of Medicine Suwon Republic of Korea.
- Department of Endocrinology and Metabolism Ajou University School of Medicine Suwon Republic of Korea.
ORCID-Profile: Ja Young Jeon, Dae Jung Kim, Kwan Woo Lee, Hae Jin Kim
Förderung
- National Research Foundation of Korea
Zitieren
APA
Heo, Y. J., Park, J., Lee, N., Choi, S. E., Jeon, J. Y., Han, S. J., Kim, D. J., Lee, K. W., & Kim, H. J. (2026). Liquiritigenin Ameliorates Metabolic Dysfunction‐Associated Steatotic Liver Disease via AMPK ‐Mediated Dual Activation of PPARα / PPARγ. Food Science & Nutrition, 14(11). https://doi.org/10.1002/fsn3.72578
Vancouver
Heo YJ, Park J, Lee N, Choi SE, Jeon JY, Han SJ, et al. Liquiritigenin Ameliorates Metabolic Dysfunction‐Associated Steatotic Liver Disease via AMPK ‐Mediated Dual Activation of PPARα / PPARγ. Food Science & Nutrition. 2026;14(11). doi:10.1002/fsn3.72578
BibTeX
@article{Heo2026,
author = {Heo, Yu Jung and Park, Jieun and Lee, Nami and Choi, Sung-E and Jeon, Ja Young and Han, Seung Jin and Kim, Dae Jung and Lee, Kwan Woo and Kim, Hae Jin},
title = {Liquiritigenin Ameliorates Metabolic Dysfunction‐Associated Steatotic Liver Disease via AMPK ‐Mediated Dual Activation of PPARα / PPARγ},
journal = {Food Science & Nutrition},
year = {2026},
volume = {14},
number = {11},
doi = {10.1002/fsn3.72578}
}
EUVIMED